From 2,000+ patients · Rybelsus vs Oral Wegovy is already seeing results
Rybelsus vs Oral Wegovy: both are FDA-approved GLP-1 medications for weight loss. Rybelsus (semaglutide) and Oral Wegovy (semaglutide) differ in mechanism and clinical efficacy. Weight Method offers both from $199/month with virtual consultations and licensed providers.
Overview
Rybelsus (FDA-approved 2019) and Oral Wegovy (FDA-approved 2025) are two separate FDA-approved daily oral tablets containing semaglutide from Novo Nordisk. Rybelsus was the first oral GLP-1 medication on the market, approved for type 2 diabetes at doses of 3–14 mg. Oral Wegovy uses a higher-dose formulation (25–50 mg) approved for chronic weight management. Weight Method does not dispense or prescribe either brand-name product; our program provides compounded semaglutide through licensed providers and U.S.-licensed pharmacies. Whether semaglutide is appropriate for you is a decision made by a licensed provider based on your individual medical profile.
Key Fact
Rybelsus (oral semaglutide 3–14 mg) is FDA-approved for type 2 diabetes. Oral Wegovy (oral semaglutide 25–50 mg) is FDA-approved for chronic weight management. Same active ingredient, different FDA-approved indications and dose ranges — and both are different from Weight Method's compounded program.
Source: FDA prescribing information (Rybelsus; Oral Wegovy)
Rybelsus
Oral Wegovy
| Rybelsus | Oral Wegovy | |
|---|---|---|
| Manufacturer | Novo Nordisk | Novo Nordisk |
| Active Ingredient | semaglutide | semaglutide |
| FDA Indication | Type 2 diabetes | Chronic weight management |
| FDA Approval | 2019 | 2025 |
| Formulation | Oral tablet | Oral tablet |
| Frequency | Once daily | Once daily |
| Available Doses | 3mg, 7mg, 14mg | 25mg, 50mg |
| Avg. Weight Loss | 5-10% | 15-17% |
| Our Price | $199/mo | $199/mo |
Key Differences
Rybelsus and Oral Wegovy both contain oral semaglutide but carry different FDA-approved indications (type 2 diabetes vs. chronic weight management) and different dose ranges (up to 14 mg vs. 25–50 mg). The mechanism class — GLP-1 receptor agonist — is the same, and both require an empty-stomach dosing protocol. Which medication and indication is clinically appropriate for any individual is determined by a licensed provider based on that person's medical history. Weight Method's program offers compounded semaglutide at $154/mo with provider oversight.
Verdict
Rybelsus and Oral Wegovy are distinct FDA-approved branded products from Novo Nordisk with different approved uses; neither is what Weight Method dispenses. The right option for an individual — and whether semaglutide is appropriate at all — depends on that person's medical profile and is determined by a licensed provider. Both background products differ from Weight Method's compounded semaglutide, available at $154/mo with provider oversight.
Your Treatment Options
Compounded GLP-1 medications dispensed by U.S.-licensed 503A pharmacies.
